Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05677971 · ClinicalTrials.gov registry record · Phase 3
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
A Phase 3 study of Alpha-1 Antitrypsin Deficiency, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT05677971: Recruiting Phase 3 study of Alpha-1 Antitrypsin Deficiency, sponsored by Takeda.
NCT05677971 is a Phase 3 study of Alpha-1 Antitrypsin Deficiency that is actively recruiting participants, run by Takeda. The registered enrollment target is 160 participants, below the 2,335-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05677971, a Phase 3 study of Alpha-1 Antitrypsin Deficiency, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo. Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.
Primary Outcome
Reduction from baseline of at least 1 stage of histologic fibrosis METAVIR staging in the centrally read liver biopsy at Week 106 in AATD-LD with METAVIR stage F2 and F3 fibrosis will be assessed.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Fazirsiran Injection
Study Locations (20)
California
- Gastroenterology & Liver Institute - Escondido
- University of California San Diego, Altman Clinical and Translational Institute - La Jolla
- UCLA Pulmonary and Critical Care - Los Angeles
- Stanford University - Palo Alto
- University of California Benioff Children's Hospital - San Francisco
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic - Phoenix
- University of Arizona Thomas D. Boyer Liver Institute - Tucson
Florida
- University of Florida - Gainesville
- Schiff Center for Liver Diseases/University of Miami - Miami
Massachusetts
- Brigham and Womens Hospital - Boston
- Boston Medical Center - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Peak Gastroenterology Associates, PC - Colorado Springs
Georgia
- Children's Healthcare of Atlanta - Atlanta
Indiana
- Indiana University School of Medicine - Indianapolis - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2030-08-14 |
| Phase | Phase 3 |
What NCT05677971 shows while recruiting
NCT05677971 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 2,335-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05677971 names 20 study sites across 12 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05677971 about?
NCT05677971 is a clinical study titled "Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein". The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran red...
What is the current status of trial NCT05677971?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2023-03-06. Estimated completion is 2030-08-14.
What conditions does trial NCT05677971 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT05677971?
The interventions under investigation include: Placebo (OTHER), Fazirsiran Injection (DRUG).
Who is sponsoring clinical trial NCT05677971?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05677971 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05677971's enrollment target sits among peer trials
160 7th of 24 higher than 18 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
RECRUITING · Phase 3
-
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
ACTIVE NOT RECRUITING · Phase 3
-
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
COMPLETED · Phase 3
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI